Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108

Human DNA Repair Genes

Wood, R., Mitchell, M., Sgouros, J., & Lindahl, T. (2001) · Science · doi:10.1126/science.1056154 · Cited by 1,719

Galectins as modulators of tumour progression

Liu, F., & Rabinovich, G. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1527 · Cited by 1,435

Control of apoptosis by p53

Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 422

New insights into long noncoding RNAs and their roles in glioma

Peng, Z., Liu, C., & Wu, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0812-2 · Cited by 375

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 335

Targeting autophagy to sensitive glioma to temozolomide treatment

Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 306

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261

Radiomics strategy for glioma grading using texture features from multiparametric MRI

Tian, Q., Yan, L., Zhang, X., Zhang, X., Hu, Y., Han, Y., Liu, Z., Nan, H., Sun, Q., Sun, Y., et al. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26010 · Cited by 221

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma

Lun, X., Wells, J. C., Grinshtein, N., King, J. C., Hao, X., Dang, N.-H., Wang, X., Aman, A., Uehling, D., Datti, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1798 · Cited by 197

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Ortíz, R., Perazzoli, G., Cabeza, L., Jiménez‐Luna, C., Luque, R., Prados, J. C., & Melguizo, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200626204005 · Cited by 187

MicroRNA in Glioblastoma: An Overview

Banelli, B., Forlani, A., Allemanni, G., Morabito, A., Pistillo, M. P., & Romani, M. (2017) · International Journal of Genomics · doi:10.1155/2017/7639084 · Cited by 171

Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization

Garnier, D., Meehan, B., Kislinger, T., Daniel, P. M., Sinha, A., Abdulkarim, B., Nakano, I., & Rak, J. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox142 · Cited by 147

Glycosylation Changes in Brain Cancer

Veillon, L. J., Fakih, C., Abou‐El‐Hassan, H., Kobeissy, F. H., & Mechref, Y. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00271 · Cited by 138

ATF3 contributes to brucine-triggered glioma cell ferroptosis via promotion of hydrogen peroxide and iron

Lu, S., Wang, X., He, C., Wang, L., Liang, S.-P., Wang, C., Li, C., Luo, T., Feng, C., Wang, Z.-C., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00700-w · Cited by 142

Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma

Taylor, M. A., Das, B. C., & Ray, S. K. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1480-9 · Cited by 143

Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma

Bastiancich, C., Vanvarenberg, K., Učakar, B., Pitorre, M., Bastiat, G., Lagarce, F., Véronique Préat, A., & Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.054 · Cited by 129

Tumour exosomes from cells harbouring PTPRZ1–MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma

Zeng, A.-L., Yan, W., Liu, Y.-W., Wang, Z., Hu, Q., Nie, E., Xin Min, Z. H. O. U., Li, R., Wang, X.-F., Jiang, T., et al. (2017) · Oncogene · doi:10.1038/onc.2017.134 · Cited by 125

Metallacarboranes on the Road to Anticancer Therapies: Cellular Uptake, DNA Interaction, and Biological Evaluation of Cobaltabisdicarbollide [COSAN] −

Fuentes, I., García‐Mendiola, T., Sato, S., Pita, M., Nakamura, H., Lorenzo, E., Teixidor, F., Marques, F., & Viñas, C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201803178 · Cited by 121

Nanoparticles: Novel vehicles in treatment of Glioblastoma

Pourgholi, F., Hajivalili, M., Jadidi‐Niaragh, F., Kafil, H. S., & Yousefi, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.014 · Cited by 120

Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide

Li, H., Yuan, X., Yan, D., Li, D., Guan, F., Yang, D., Wang, H., Liu, X., & Yang, B. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478917 · Cited by 113

LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma

Liu, B., Zhou, J., Wang, C., Chi, Y., Wei, Q., Fu, Z., Lian, C., Huang, Q., Liao, C., Yang, Z., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2540-y · Cited by 113

Deep Learning of Imaging Phenotype and Genotype for Predicting Overall Survival Time of Glioblastoma Patients

Tang, Z., Xu, Y., Jin, L., Aibaidula, A., Lu, J., Jiao, Z., Wu, J., Zhang, H., & Shen, D. G. (2020) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2020.2964310 · Cited by 108

Nucleic acid drug vectors for diagnosis and treatment of brain diseases

Lü, Z., Shen, J., Yang, H. J., Wang, J., Zhao, R., Zhang, T.-L., Guo, J. R., & Zhang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01298-z · Cited by 116

Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms

Gupta, A., Singh, A. K., Kumar, R., Ganguly, R., Rana, H. K., Pandey, P. K., Sethi, G., Bishayee, A., & Pandey, A. K. (2019) · Molecules · doi:10.3390/molecules24183399 · Cited by 102

Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8

Berenguer, J., Lagerweij, T., Zhao, X. W., Dusoswa, S. A., van der Stoop, P. P. M., Westerman, B. A., de Gooijer, M. C., Zoetemelk, M., Zomer, A., Crommentuijn, M. H. W., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1446660 · Cited by 101

An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme—Role in Pathogenesis and Therapeutic Perspective

Pawłowska, E., Szczepańska, J., Szatkowska, M., & Błasiak, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030889 · Cited by 100

JNK Pathway in CNS Pathologies

Corrales, T. D. L. R., Losada‐Pérez, M., & Casas‐Tintó, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083883 · Cited by 92

The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response

D’Alessandris, Q. G., Biffoni, M., Martini, M., Runci, D., Buccarelli, M., Cenci, T., Signore, M., Stancato, L. F., Olivi, A., Maria, R. D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now304 · Cited by 87

Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma

Przystal, J. M., Waramit, S., Pranjol, M. Z. I., Yan, W., Chu, G., Chongchai, A., Samarth, G. M., Olaciregui, N. G., Tabatabai, G., Carcaboso, A. M., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201708492 · Cited by 89

Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches

Miranda, A., Blanco‐Prieto, M. J., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.056 · Cited by 87

Galectin-1 inhibitors and their potential therapeutic applications: a patent review

Blanchard, H., Bum‐Erdene, K., Bohari, M. H., & Yu, X. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1163338 · Cited by 84

An Insight into the Increasing Role of LncRNAs in the Pathogenesis of Gliomas

Yan, Y., Xu, Z., Li, Z., Sun, L., & Gong, Z. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00053 · Cited by 78

Vimentin as a potential target for diverse nervous system diseases

Wang, T., Qiu, X., Wu, H., Chen, K., Liu, S., Li, Y., He, T., & Zhao, J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355744 · Cited by 77

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options

Gao, H., Xi, Z., Dai, J., Xue, J., Guan, X., Zhao, L., Chen, Z., & Xing, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02005-y · Cited by 81

Glioblastoma cells vampirize WNT from neurons and trigger a JNK/MMP signaling loop that enhances glioblastoma progression and neurodegeneration

Portela, M., Venkataramani, V., Fahey-Lozano, N., Seco, E., Losada‐Pérez, M., Winkler, F., & Casas‐Tintó, S. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000545 · Cited by 81

miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma

Li, Y., Liu, Y., Ren, J. F., Deng, S., Yi, G., Guo, M., Shu, S., Zhao, L., Peng, Y.-P., & Qi, S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2835-3 · Cited by 74

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma

Wang, B., Peng, F., Huang, W., Zhou, J., Zhang, N., Sheng, J., Haruehanroengra, P., He, G., & Han, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.013 · Cited by 73

The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas

Chen, D., Rauh, M., Buchfelder, M., Eyüpoglu, I. Y., & Savaskan, N. E. (2017) · Oncotarget · doi:10.18632/oncotarget.17737 · Cited by 72

Modulation ofMKNK2alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment

Mogilevsky, M., Tepper, O., Kumar, S., Mogilevsky, A., Keshet, E., Yavin, E., Heyd, F., & Karni, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky921 · Cited by 69

The RNA-Binding Ubiquitin Ligase MEX3A Affects Glioblastoma Tumorigenesis by Inducing Ubiquitylation and Degradation of RIG-I

Bufalieri, F., Caimano, M., Severini, L. L., Basili, I., Paglia, F., Sampirisi, L., Loricchio, E., Petroni, M., Canettieri, G., Santoro, A., et al. (2020) · Cancers · doi:10.3390/cancers12020321 · Cited by 65

β‐asarone inhibited cell growth and promoted autophagy via P53/Bcl‐2/Bclin‐1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells

Wang, N., Zhang, Q., Luo, L., Ning, B., & Fang, Y. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26118 · Cited by 68

Small‐Molecule Kinase‐Inhibitors‐Loaded Boron Cluster as Hybrid Agents for Glioma‐Cell‐Targeting Therapy

Couto, M., Mastandrea, I., Cabrera, M., Cabral, P., Teixidor, F., Cerecetto, H., & Viñas, C. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701965 · Cited by 67

Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma

Mooney, J. H., Bernstock, J. D., Ilyas, A., Ibrahim, A. G. A., Yamashita, D., Markert, J. M., & Nakano, I. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.05.205 · Cited by 65

Impact of Galectins in Resistance to Anticancer Therapies

Navarro, P., Martínez‐Bosch, N., Blidner, A. G., & Rabinovich, G. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3870 · Cited by 65

Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas

Xiao, D., Huang, J. X., Pan, Y., Li, H. R., Fu, C., Mao, C., Cheng, Y., Shi, Y., Chen, L., Jiang, Y., et al. (2016) · Theranostics · doi:10.7150/thno.17032 · Cited by 62

Green sol–gel synthesis of hydroxyapatite nanoparticles using lemon extract as capping agent and investigation of its anticancer activity against human cancer cell lines (T98, and SHSY5)

Baladi, M., Amiri, M., Mohammadi, P., Mahdi, K. S., Golshani, Z., Razavi, R., & Salavati‐Niasari, M. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104646 · Cited by 60

Gemcitabine and glioblastoma: challenges and current perspectives

Bastiancich, C., Bastiat, G., & Lagarce, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.010 · Cited by 60

Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide

Melamed, J. R., Morgan, J. T., Ioele, S. A., Gleghorn, J. P., Sims‐Mourtada, J., & Day, E. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25467 · Cited by 60

Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy

Guan, X., Hasan, M. N., Begum, G., Kohanbash, G., Carney, K. E., Pigott, V. M., Persson, A. I., Castro, M. G., Jia, W., & Sun, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1062-3 · Cited by 61

Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance

Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Zhong, L., Zhou, H., Tang, Z., Li, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02567-3 · Cited by 71

Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients

Lin, L., Wang, G., Ming, J., Meng, X., Han, B., Sun, B., Cai, J., & Jiang, C. (2016) · Tumor Biology · doi:10.1007/s13277-016-5462-7 · Cited by 58

TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells

Tian, T., Li, A., Lu, H., Luo, R., Zhang, M., & Li, Z. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.115 · Cited by 58

Molecular and Circulating Biomarkers in Patients with Glioblastoma

Senhaji, N., Houssaini, A. S., Lamrabet, S., Louati, S., & Bennis, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137474 · Cited by 60

Design of temozolomide-loaded proliposomes and lipid crystal nanoparticles with industrial feasible approaches: comparative assessment of drug loading, entrapment efficiency, and stability at plasma pH

Waghule, T., Rapalli, V. K., Singhvi, G., Gorantla, S., Khosa, A., Dubey, S. K., & Saha, R. N. (2020) · Journal of Liposome Research · doi:10.1080/08982104.2020.1748648 · Cited by 57

Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles

Miranda, A., Blanco‐Prieto, M. J., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.049 · Cited by 58

TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ

Lu, H. J., Xiao, J., Ke, C., Ni, X., Xiu, R., Tian, Q., Pan, H., Zou, L., Wang, F., Ma, T., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1805-9 · Cited by 55

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine

Stritzelberger, J., Distel, L. V., Buslei, R., Fietkau, R., & Putz, F. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1743-x · Cited by 53

Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway

Soukhtanloo, M., Mohtashami, E., Maghrouni, A., Mollazadeh, H., Mousavi, S. H., Roshan, M. K., Tabatabaeizadeh, S., Hosseini, A., Vahedi, M. M., Jalili‐Nik, M., et al. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00081-7 · Cited by 51

FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy

He, C. H., Lu, S., Wang, X., Wang, C., Wang, L., Liang, S.-P., Luo, T., Wang, Z.-C., Piao, M., Chi, G., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00663-y · Cited by 51

Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway

Yin, H., & Cui, X. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3575 · Cited by 50

LGALS3 Promotes Treatment Resistance in Glioblastoma and Is Associated with Tumor Risk and Prognosis

Wang, H., Song, X., Huang, Q., Xu, T., Yun, D., Wang, Y., Hu, L., Yan, Y., Chen, H., Li, J., et al. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0638 · Cited by 51

Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment

Hudson, A. L., Parker, N., Khong, P., Parkinson, J., Dwight, T., Ikin, R. J., Zhu, Y., Chen, J., Wheeler, H., & Howell, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00314 · Cited by 46

Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma

Rajesh, Y., Biswas, A., Kumar, U., Das, S., Banerjee, I., Banik, P., Bharti, R., Nayak, S., Ghosh, S. K., & Mandal, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.025 · Cited by 45

Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma

Liu, B., Liu, J., Liao, Y., Chen, J., Zhang, Z., Zhao, J., Liu, K., Huang, H., Cao, H., & Cheng, Q. (2019) · Medical Science Monitor · doi:10.12659/msm.916648 · Cited by 46

Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF

Wang, C., He, C. H., Lu, S., Wang, X., Wang, L., Liang, S.-P., Wang, X., Piao, M., Cui, J., Chi, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02866-3 · Cited by 46

FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways

Yihan, W., Li, D., Bao, S., Wang, M., Yun, Y.-L., & Zhu, R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.051 · Cited by 45

Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH ‐mutated gliomas revealed by mass spectrometry imaging

Kampa, J. M., Kellner, U., Marsching, C., Guevara, C. R., Knappe, U. J., Sahin, M., Giampà, M., Niehaus, K., & Bednarz, H. (2020) · Neuropathology · doi:10.1111/neup.12671 · Cited by 45

Connexin 43 confers chemoresistance through activating PI3K

Pridham, K. J., Shah, F., Hutchings, K. R., Sheng, K. L., Guo, S., Liu, M., Kanabur, P., Lamouille, S., Lewis, G., Morales, M., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00378-7 · Cited by 43

Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics

Thapa, R., Afzal, M., Goyal, A., Gupta, G., Bhat, A. A., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Shahwan, M. J., Kukreti, N., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122613 · Cited by 44

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide

Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Marzo, D. D., Barone, D., Capone, F., Pentimalli, F., & Giordano, A. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4788 · Cited by 42

Gold-based nanomaterials for the treatment of brain cancer

Tu, L., Luo, Z., Wu, Y., Huo, S., & Liang, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0524 · Cited by 43

LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma

He, X., Sheng, J., Yu, W., Wang, K., Zhu, S., & Liu, Q. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00898-z · Cited by 42

Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin αv in Glioblastoma Cells

Yu, Q., Xiao, W., Sun, S., Sohrabi, A., Liang, J., & Seidlits, S. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.616580 · Cited by 44

Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

Chou, S., Yen, S., Huang, C., & Huang, E. (2018) · BMC Cancer · doi:10.1186/s12885-018-4025-2 · Cited by 39

A biodegradable nanocapsule for through-skull NIR-II fluorescence imaging/magnetic resonance imaging and selectively enhanced radio-chemotherapy for orthotopic glioma

Yin, N., Wang, Y., Cao, Y., Huang, Y., Jin, L., Zhang, S., Liu, J., Zhang, T., Lv, Z., Liu, Y., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101619 · Cited by 40

Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization

Hinrichs, C. N., Ingargiola, M., Käubler, T., Löck, S., Temme, A., Köhn‐Luque, A., Deutsch, A., Vovk, O. I., Stasyk, O. V., & Kunz‐Schughart, L. A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0807 · Cited by 39

Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair

Kim, G. W., Lee, D. H., Yeon, S.-K., Jeon, Y. H., Yoo, J. H., Lee, S. W., & Kwon, S. H. (2019) · Anticancer Research · doi:10.21873/anticanres.13888 · Cited by 39

CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells

Xue, B., Xiang, W., Zhang, Q., Wang, H., Zhou, Y., Tian, H., Abdelmaksou, A., Xue, J., Sun, M., Yi, D., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02458-8 · Cited by 39

Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma

Pena, E. S., Graham-Gurysh, E. G., Bachelder, E. M., & Ainslie, K. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313160 · Cited by 44

Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage

Shen, C. J., Kummerlowe, M. N., Redmond, K. J., Martínez-Gutiérrez, J. C., Usama, S. M., Holdhoff, M., Grossman, S. A., Laterra, J., Strowd, R. E., III, & Kleinberg, L. R. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.06.005 · Cited by 38

YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway

Tong, H., Zhao, K., Zhang, J., Zhu, J., & Xiao, J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s185514 · Cited by 37

LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR‐134/Myc/ABCC1 axis in glioma

Wu, C., Su, J., Long, W., Qin, C., Wang, X., Xiao, K., Yang, L., Xiao, Q., Wang, J., Pan, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15846 · Cited by 38

The multifaceted PDCD10/CCM3 gene

Valentino, M., Dejana, E., & Malinverno, M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.12.008 · Cited by 39

Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity

Marwah, R., Xing, D. T., Squire, T., Soon, Y. Y., Gan, H. K., & Ng, S. P. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04441-0 · Cited by 36

Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme

Senbabaoglu, F., Cingöz, A., Kaya-Aksoy, E., Kazancioglu, S., Lack, N. A., Açılan, C., & Onder, T. B. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167292 · Cited by 35

Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review

Ferreira, J. S. P. D. M., Ramos, A. A., Almeida, T., Azqueta, A., & Rocha, E. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.04.062 · Cited by 35

Anti-cancer Effects of Fucoxanthin on Human Glioblastoma Cell Line

Lopes, F. G., de Oliveira, K. A., Lopes, R. G., Poluceno, G. G., Simioni, C., Pescador, G. D. S., Bauer, C. M., Maraschin, M., Dérner, R. B., Garcez, R. C., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14703 · Cited by 37

A novel polysaccharide derived from algae extract induces apoptosis and cell cycle arrest in human gastric carcinoma MKN45 cells via ROS/JNK signaling pathway

Xie, P., Fujii, I., Zhao, J.-E., Shinohara, M., & Matsukura, M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3658 · Cited by 35

Sulforaphane induces apoptosis and inhibits invasion in U251MG glioblastoma cells

Zhang, Z., Li, C., Shang, L., Zhang, Y., Zou, R., Zhan, Y., & Bi, B. (2016) · SpringerPlus · doi:10.1186/s40064-016-1910-5 · Cited by 34

LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway

Zhong, C., Chen, Y., Tao, B., Peng, L., Peng, T., Yang, X., Xia, X., & Chen, L. (2018) · BMC Cancer · doi:10.1186/s12885-018-4649-2 · Cited by 33

TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas

Tong, S., Yu, H., Xu, Y., Sun, Q., Ye, L., Cai, J., Ye, Z., Chen, Q., & Tian, D. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113474 · Cited by 33

Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia‐inducible factor 1α/hedgehog pathway under hypoxia

Wei, M., Ma, R., Huang, S., Liao, Y., Ding, Y., Li, Z., Guo, Q., Tan, R. X., Zhang, L., & Zhao, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28361 · Cited by 33

Cytotoxic Effects of Chlorophyllides in Ethanol Crude Extracts from Plant Leaves

Wang, Y.-T., Yang, C.-H., Huang, T.-Y., Tai, M., Sie, R.-H., & Shaw, J. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/9494328 · Cited by 32

Chronic exposure of human glioblastoma tumors to low concentrations of a pesticide mixture induced multidrug resistance against chemotherapy agents

Doğanlar, O., Doğanlar, Z. B., Kurtdere, A. K., Chasan, T., & Ok, E. S. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110940 · Cited by 33

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway

Li, K., Ouyang, L., He, M., Luo, M., Cai, W., Tu, Y., Pi, R., & Liu, A. (2017) · Oncotarget · doi:10.18632/oncotarget.15868 · Cited by 31

MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

Chen, Y., Li, R. Q., Pan, M., Shi, Z., Yan, W., Liu, N., You, Y., Zhang, J., & Wang, X. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2463-3 · Cited by 31

Insulin signaling mediates neurodegeneration in glioma

Jarabo, P., de Pablo, C., Herranz, H., Martín, F. A., & Casas‐Tintó, S. (2021) · Life Science Alliance · doi:10.26508/lsa.202000693 · Cited by 31

TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1

Wei, J., Wang, L., Zhang, Y., Sun, T., Zhang, C., Hu, Z., Zhou, L., Liu, X., Wan, J., & Ma, L. (2023) · Oncogene · doi:10.1038/s41388-023-02717-3 · Cited by 31

DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide

Zhao, M., Tan, B., Dai, X., Shao, Y., He, Q., Yang, B., Wang, J., & Weng, Q. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172665 · Cited by 31

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

Cai, H., Liu, A.-S., Zhang, M.-J., Liu, H.-J., Meng, X., Qian, H.-P., & Wan, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00669 · Cited by 30

Anticancer Potential of Temozolomide-Loaded Eudragit-Chitosan Coated Selenium Nanoparticles: In Vitro Evaluation of Cytotoxicity, Apoptosis and Gene Regulation

Mazarei, M., Arvejeh, P. M., Mozafari, M. R., Khosravian, P., & Ghasemi, S. (2021) · Nanomaterials · doi:10.3390/nano11071704 · Cited by 30

Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems

Petrenko, D. А., Chubarev, V. N., Syzrantsev, N., Ismail, N. M., Меркулов, В. А., Sologova, S. S., Grigorevskikh, E., Smolyarchuk, Е. А., & Alyautdin, R. N. (2022) · Molecules · doi:10.3390/molecules27113507 · Cited by 30

Research progress of drug resistance mechanisms to temozolomide in glioblastoma: A narrative review

Lu, A. (2022) · Glioma · doi:10.4103/glioma.glioma_24_22 · Cited by 2

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 422

Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance

(2026) · Journal of Chemical Biological and Physical Sciences · doi:10.24214/jcbps.a.16.1.09816

Novel strategies to overcome chemoresistance in human glioblastoma

Tang, Q., Ren, T., Bai, P., Wang, X., Zhao, L., Zhong, R., & Sun, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116588 · Cited by 24

Molecular mechanisms in temozolomide-resistant glioblastoma

Lee, S. Y., & Kitange, G. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00029-4 · Cited by 1